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Abstract  19 
Early pregnancy loss (EPL) between days 15 to 65 after breeding has been shown to occur in 7.9% 20 
of equine pregnancies with substantial economical, welfare and safety implications. Whilst 21 
maternal age has been recognised as an important risk factor in relation to the incidence of EPL, 22 
few other risk factors have been conclusively identified.  Further, multivariable data analysis of risk 23 
factors for EPL is sparse.  A prospective cohort investigation of thoroughbred broodmares in the 24 
United Kingdom was conducted over the 2013 and 2014 breeding seasons. Information relating to 25 
28 factors including mare, stallion, pregnancy and therapeutic interventions was collected using 26 
questionnaires and entered into a custom-designed Microsoft Access database. Mixed effects 27 
logistic regression was used to determine risk factors for EPL, including ‘mare’ as a random effect 28 
to account for repeat pregnancies in the same mare. Stallion, stud and veterinarian were also 29 
evaluated as random effects. Variables with a p-value of <0.25 in univariable analysis were taken 30 
forward for consideration in the multivariable model which was built using a forward stepwise 31 
approach. Data were collected on 2245 pregnancies in 1753 mares. Increasing mare age (OR=1.11, 32 
95% confidence interval (CI)=1.04, 1.18, p=0.001), having had one previous foal (OR=3.52, 95% 33 
CI=1.56, 7.95, p=0.002) and presence of uterine cysts (OR=1.76, 95% CI=1.07, 2.91, p=0.03) were 34 
all associated with increased odds of EPL following multivariable analysis.  Increasing day 15/16 35 
scan vesicle size (OR=0.24, 95% CI=0.16, 0.38, p<0.001) and the use of ovulatory induction agents 36 
(OR=0.31, 95% CI=0.17, 0.55, p<0.001) were negatively associated with EPL. Stallion, stud and 37 
veterinarian were not significantly associated with EPL. Analysis of a subpopulation of 344 multiple 38 
(twin and triplet) pregnancies found that the use of flunixin meglumine at the time of manual 39 
reduction of a multiple pregnancy resulted in reduced odds of EPL (OR=0.34, 95% CI=0.14, 0.84, 40 
p=0.02). Results from this study can be used by stud farm personnel when assessing their 41 
broodmare population and by clinicians when deciding upon therapeutic strategies. Additional 42 
work can be focused around these risk factors to further our understanding of the 43 
pathophysiology of EPL.  44 
 45 
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1. Introduction 51 
Numerous studies have shown that the majority of losses of thoroughbred pregnancies occur in 52 
the embryonic and early fetal period [1-3]. Pregnancy losses have significant implications in terms 53 
of economics, time and mare and stallion welfare [4, 5]. Despite this, few studies have looked at 54 
risk factors specifically relating to early pregnancy loss (EPL). Furthermore, most studies 55 
investigating overall reproductive efficiency report risk factors for EPL identified using univariable 56 
rather than multivariable analysis [3, 6-8] and thus do not take account of potential confounding 57 
due to associations between proposed risk factors, which may lead to erroneous conclusions.  58 
 59 
Univariable analyses repeatedly show mare age to be the most significant factor impacting on the 60 
incidence of EPL, with increasing age linked to increases in losses [3, 6, 7].  The start of season 61 
reproductive status of the mare has also repeatedly been found to relate to incidence of loss, with 62 
maiden mares consistently reported to have the lowest incidences of EPL [3, 6, 7]. There is, 63 
however, a clear association between mare age and status with maiden mares principally being 64 
the youngest members of the cohort. Conflicting results have been found in relation to foaling to 65 
covering period and uterine cysts [2, 9, 10]. Whilst the contribution of a range of reproductive 66 
therapies on various aspects of reproductive efficiency have been measured [7, 11, 12] there is 67 
little work investigating their impact on EPL. 68 
 69 
Manual reduction of twins is common practice in broodmares [13] and various medications are 70 
used at the time of reduction in attempts to minimise its impact on the remaining conceptus [14, 71 
15]. The effect of the individual operator and the use of the prostaglandin synthetase inhibitor 72 
flunixin are the most common factors investigated in relation to pregnancy loss in twin 73 
pregnancies [14-16]. Again, investigations into their effect on EPL have only been conducted with 74 
univariable analyses and results of studies have been contradictory [14, 16, 17]. 75 
 76 
Multivariable analyses investigating reproductive efficiency in thoroughbreds more broadly were 77 
conducted in a 2012 study of 1482 New Zealand mares [9] and a 2016 study of 2385 mares in 78 
Ireland [18]. These studies looked at pregnancy rates, mating to conception times and pregnancy 79 
loss overall (day 15 to term) but did not investigate factors specifically influencing EPL. A 2011 80 
study of 1476 Japanese thoroughbreds did use multivariable analysis to investigate factors 81 
associated with losses up to day 35 of pregnancy [2]. They found foal heat mating and the 82 
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presence of uterine cysts to contribute to the incidence of EPL (defined as loss from gestational 83 
day 17-35). This study did not, however, assess the impact of therapeutic agents, stallions or twin 84 
pregnancies on pregnancy outcome.  85 
 86 
With few diagnostic and therapeutic options available to minimise the incidence of EPL, 87 
investigations to understand risk factors associated with the condition are paramount.  A 88 
comprehensive multivariable study to address risk factors associated with EPL in this population of 89 
thoroughbred mares was, therefore, warranted. We hypothesised that a combination of mare, 90 
stallion, conceptus and therapeutic factors would all independently contribute to the risk of EPL 91 
with the greatest risk being mare age.  We also proposed that of the factors associated with mare 92 
age, uterine cysts but not post mating uterine fluid or mare status would independently increase 93 
the risk of EPL.  Further, based on the observation by Kohne et al, 2014 that hCG administered to 94 
induce ovulation results in increased levels of progesterone 5-15 days post ovulation, we proposed 95 
that use of ovulatory agents would reduce the risk of EPL. The objectives of this study were to 96 
investigate the effects of (i) mare, stallion, pregnancy and therapeutic level variables on EPL and 97 
(ii) therapies/factors associated with twin or triplet reduction on EPL, using multivariable analysis.  98 
  99 
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2. Materials and methods 100 
2.1. Study design and period 101 
A prospective cohort study was conducted recording details on the reproductive management and 102 
occurrence of EPL in thoroughbred broodmares located on 29 stud farms under the care of two 103 
large equine veterinary practices based in Newmarket, UK. Data were collected over the 2013 and 104 
2014 breeding seasons and the results of a descriptive analysis of the data have been reported [1]. 105 
The definition of EPL was pregnancy loss from day of detection to gestation day 65. This was to 106 
account for losses occurring in the embryonic period as well as during early implantation and 107 
microcotyledon development.  108 
2.2. Sample size calculation  109 
Sample size calculations were conducted using the online software Epitools Epidemiological 110 
Calculators (AusVet Pty Ltd). Calculations for the risk factor analysis assuming 80% power and a 111 
30-40% exposure frequency in controls indicated around 140 cases of EPL (and the same number 112 
of controls) would be required to detect an odds ratio of 2 as statistically significant at a 5% level.  113 
2.3 Data collection and processing  114 
Data were collected from a combination of sources. An initial questionnaire was completed by 115 
stud secretaries, attending veterinarians or one of the investigators at the time of the initial 116 
positive pregnancy scan 11 to 17 days post covering.  Mare, stallion and veterinary reproductive 117 
data were recorded. A further questionnaire was completed at each subsequent reproductive scan 118 
until gestation day 65. Additional information was collected from two veterinary hospital 119 
databases, Weatherbys (Wellingborough, UK) and Racing Post online 120 
(https://www.racingpost.com/bloodstock/).  The inclusion criterion for a mare to be entered into 121 
the study was a positive day 14 to 17 routine pregnancy scan. Data were only collected for mares 122 
with clinical findings recorded throughout the entire period of early pregnancy (days 15-65). 123 
Therefore only pregnancies with a known pregnancy status at 65 days of gestation as ascertained 124 
by ultrasonography or birth of a live foal of pregnancy were included in the analysis. Data collected 125 
were entered into a custom designed Microsoft Access database and stud, veterinarian, stallion 126 
and mare names were coded to ensure anonymity. Data were transferred to Microsoft Excel and 127 
subsequently to Stata software package for statistical analysis. The total number of cases included 128 
for each variable is listed in Supplementary Tables 1 and 2). 129 
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2.4 Statistical analysis 130 
2.4.1 Risk factors for EPL  131 
Incidence of EPL was derived for different levels of each exposure variable, together with 95% 132 
confidence intervals (CI). Mixed effects logistic regression was conducted to identify factors 133 
associated with EPL, and odds ratio (OR) and its 95% CI reported. Mare was included as a random 134 
effect in all analyses, to account for repeat pregnancies in the same mare within the dataset. A 135 
total of 22 exposure variables (listed in Supplementary Table 1) were evaluated as fixed effects in 136 
univariable analyses. Continuous variables were initially categorised to evaluate the linearity of 137 
their association with the outcome. Where no departure from linear trend was identified using a 138 
likelihood ratio test (LRT), the variable was subsequently modelled as continuous predictor in the 139 
analysis. Variables with a univariable LRT p-value of <0.25 were considered for inclusion in a 140 
multivariable model, which was built using a forward stepwise approach. Inclusion of a variable in 141 
the final model was based on a LRT p-value of <0.05. Biologically plausible interactions between 142 
variables in the final model were assessed using a LRT comparing models with and without the 143 
interaction terms.  Given the number of levels, stud farm, stallion and veterinarian were assessed 144 
as random effects both on their own (i.e. with no other variables included in the model) and in the 145 
final model, regardless of their univariable p-value. As an a priori variable of interest, stallion was 146 
also evaluated as a fixed effect using a subset of the data including only stallions with >30 147 
pregnancies in the dataset [7]. In this analysis, stallion was added to a multivariable model 148 
containing the variables found to be significantly associated with EPL in the main analysis, using 149 
the stallion with most observations as the reference category.  150 
2.4.2. Risk factor analysis for EPL in multiple pregnancies  151 
A separate analysis was also conducted to investigate risk factors associated with EPL specifically 152 
relating to multiple (twin or triplet) pregnancies. With previous studies having indicated that 153 
veterinary operator may have an effect on pregnancy outcome following manual reduction [16], 154 
‘vet’ was included in this analysis as a fixed effect. Stud and stallion were evaluated for inclusion as 155 
random effects. This dataset included nine mares with repeated pregnancies. For these mares, 156 
one pregnancy was randomly selected for inclusion in the analysis, using a random number 157 
generator. The other pregnancies from these mares were removed, resulting in a dataset with 158 
only one pregnancy per mare.  The fixed effect of day 15 or 16 vesicle size used the size of the 159 
conceptus which was not subject to manual reduction. Variables with a univariable LRT p-value of 160 
<0.25 were considered for inclusion in a multivariable model. Additionally, all factors found to be 161 
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significant in the final multivariable analysis of the ‘all pregnancies’ dataset were considered for 162 
inclusion in the final model, regardless of their significance in the univariable analysis, as was the 163 
‘vet’ variable. A forward stepwise building process was used with a p value of <0.05 considered 164 
significant in the final model.  165 
  166 
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3. Results 167 
3.1. Descriptive results  168 
Information was collected on 2245 pregnancies in 1753 mares, 492 of which had repeat 169 
pregnancies in the dataset either due to a pregnancy in both 2013 and 2014 or because they lost a 170 
pregnancy and had a second or third pregnancy within the same season. Mares were located on 171 
29 different stud farms and were covered by a total of 86 stallions. Veterinary care was provided 172 
by 13 veterinarians. The overall incidence of EPL in this population was 7.9% (178/2245; 95% 173 
CI=6.8, 9.1). A description of the risk factors investigated, the levels for each factor and the 174 
incidence of EPL for each level can be seen in Supplementary Table 1A-D.   175 
3.2 Factors associated with EPL  176 
Univariable analysis was performed on 22 potential risk factors.  A total of five mare factors (age, 177 
status, EPL previous season, number previous live foals, uterine cysts), two therapeutic factors 178 
(ovulatory induction agents, oxytocin at cover) and one pregnancy factor (size of day 15/16 179 
vesicle) had an overall LRT p-value <0.25 and went forward for assessment in a multivariable 180 
model.  181 
 182 
The final multivariable model is presented in Table 1. Mare age, the number of previous live foals 183 
and uterine cysts were associated with increased odds of EPL whereas the use of an ovulatory 184 
induction agent (3000 iu Chorulon (MSD Animal Health, Milton Keynes, UK) intravenously, 2.1 mg 185 
Ovuplant® (Dechra Veterinary Products, Shrewsbury, UK) or 0.04 mg Receptal® (MSD Animal 186 
Health, Milton Keynes, UK)) and increasing size of the embryonic vesicle at gestation day 15 or 16 187 
reduced EPL occurrence. Stud, vet or stallion were not significant when included in this model as 188 
random effects and no significant interactions were identified.  189 
 190 
3.3. Effect of stallion on EPL 191 
A total of 22 stallions were represented in the data set 30 or more times with the incidence of EPL 192 
amongst these stallions ranging from 1.5% (95% CI=0.0, 8.2) to 16.2% (95% CI=6.2, 32.0). The 193 
overall effect of stallion was not statistically significant (p=0.07) after accounting for other factors 194 
associated with EPL. Just one stallion had significantly higher odds of EPL compared to the 195 
reference stallion (OR=8.5, 95% CI=2.1, 35.0, p=0.003).   196 
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3.4. Multiple pregnancy dataset 197 
A sub-population of 344 mares with multiple pregnancies was analysed representing 26 stud farms 198 
and 57 covering stallions.  Incidence of EPL in this sub-population was 7.6% (26/344; 95% CI=5.0, 199 
10.9). Univariable analysis was performed on 28 factors described in Supplementary Table 2A-D.  200 
Of these, five mare factors (age, status, EPL previous season, number of previous live foals, uterine 201 
cysts), three therapeutic factors (ovulatory induction agents, dexamethasone at cover and uterine 202 
lavage) and four twinning factors (flunixin meglumine, sedation, same location at reduction, 203 
multiple ovulations in the same versus bilateral ovaries) had a univariable LRT p-value of <0.25 and 204 
were, therefore, considered for inclusion in the multivariable model. The final model found mare 205 
age, the use of ovulatory induction agents, the use of dexamethasone at cover and the use of 206 
flunixin at twin pregnancy reduction to be significantly associated with EPL (Table 2). Veterinarian 207 
was not significantly associated with EPL, either in univariable analysis (p=0.27) or when forced 208 
into the final multivariable model (p=0.42), and neither were stallion or stud farm.  209 
  210 
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4. Discussion 211 
This is the largest study to date to describe a multivariable approach for the investigation of 212 
factors influencing EPL in thoroughbred mares. Key findings were the increased occurrence of EPL 213 
in the presence of uterine cysts and the reduction in EPL associated with the use of ovulatory 214 
induction agents (chorulon and deslorelin) and flunixin to treat twin pregnancies at the time of 215 
reduction. In agreement with previous studies using univariable approaches, results show the 216 
important contribution of maternal age on pregnancy loss and an increased risk of EPL associated 217 
with small vesicle sizes. Whilst mare status has been widely thought to contribute to EPL [3, 6, 7], 218 
multivariable findings show status per se to be unrelated to EPL although animals which had had a 219 
single previous foal were at increased risk of EPL when compared to maiden mares. These findings 220 
open avenues for ongoing investigations to allow underlying causes of EPL to be more 221 
comprehensively understood whilst also assisting clinicians wishing for evidence based rationales 222 
in management of broodmares. 223 
 224 
Studies using univariable analysis have repeatedly shown mare age to be a well-recognised factor 225 
associated with an increased risk of EPL [3, 5, 7, 19]. Although an odds ratio of 1.11 per year may 226 
seem low, this would lead to a 15-year-old mare having an OR for EPL of 2.84 in comparison with a 227 
5 year-old-mare. The transfer of oocytes from aged mares to young recipient mares and vice versa 228 
indicates that the main contributor to reduced fertility in early pregnancy is an age-related decline 229 
in oocyte quality rather than uterine factors [20, 21]. Cytogenetic studies in humans have shown 230 
45-70% of all first trimester losses to be attributed to chromosomal anomalies and that this 231 
proportion increased substantially with maternal age [22, 23]. The contribution of chromosomal 232 
abnormalities to EPL in the mare is not currently known, although two chromosomal abnormalities 233 
have been demonstrated experimentally in equine embryos [24] and new methods to study 234 
conceptual material from clinically failed pregnancies are now available [25]. It is also plausible 235 
that EPL derived from oocyte defects could arise by mitochondrial defects or chromosome 236 
misalignment on the metaphase II spindle which have been shown to increase in aged mares [26, 237 
27]. These oocyte abnormalities are likely to also contribute to earlier pregnancy losses (prior to 238 
day 15) not assessed as part of this study.  239 
 240 
Early pregnancy vesicle size, as determined at routine ultrasound examinations, has previously 241 
been shown to be associated with EPL [28-30], however, the magnitude of this effect has not 242 
previously been quantified. The current study shows that for each cm increase in vesicle size at 243 
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gestational day 15 or 16, the odds of EPL were reduced by a factor of 0.28. It is possible that 244 
intrinsic flaws within the oocyte or early conceptus result in a smaller vesicle size and, hence, this 245 
is a visual sign representative of an underlying pathology. Conversely, it may be that a small yet 246 
viable vesicle is more likely to result in failure due to an inability to adequately progress within the 247 
uterus. For example, we know that contact between the conceptus and maternal endometrium is 248 
essential for maternal recognition of pregnancy [31].  249 
 250 
The relationship between parity and EPL has not previously been described. The findings of a 251 
foaled uterus (one live foal) being at higher risk of losing a pregnancy than a maiden uterus seem 252 
relatively intuitive. Increasing parity is known to coincide with a lengthening of the vulva and an 253 
increased angle of declination [32]. Further, fixation in a previously gravid horn in consecutive 254 
pregnancies can results in a higher incidence of early pregnancy loss [33], a possibility after one 255 
live foal. Loss of structural support of the caudal reproductive tract and the broad ligament 256 
resulting from repeat pregnancies may result in the uterus tilting ventrocaudally and scintigrams 257 
taken after intrauterine infusion of radiocolloid revealed the position of the uterus may affect 258 
uterine clearance [34]. Therefore, it was of note that we did not identify delayed uterine clearance 259 
as a risk factor for EPL in this study. Additionally, links between parity and endometrosis have 260 
been found [35], as have links relating elastosis of the myometrial vessels to parity [36].  These 261 
studies also reported the presence of elastosis in the myometrial vessels to be related to chronic 262 
uterine infection and delayed uterine clearance with the number of previous foals being found to 263 
have the strongest association with uterine vascular degeneration.  Therefore one would have 264 
expected the risk to extend beyond one live foal to 2-5 and 6+ foals, although statistically this was 265 
not the case. This specific risk of one live foal over 2-5 is currently unexplained.  266 
 267 
There has been a substantial increase in the use of ovulatory induction agents in the UK from 268 
59.1% in 2002 to 91.8% in 2013/14 [1, 7]. Although primarily used to reduce the number of covers 269 
per oestrous cycle, here we show ovulatory agents are associated with a reduced odds of EPL. The 270 
exact mechanisms remain unknown.   Timing of ovulation in respect to cover is known to impact 271 
on EPL and it is speculated that an oocyte ageing in the oviduct post ovulation and prior to 272 
fertilisation may reduce oocyte quality [37] and increase the likelihood of the pregnancy being lost 273 
[38].  None of the oocytes in our study had ovulated at the last reproductive evaluation prior to 274 
cover (typically 12 to 24 hours prior to mating). Furthermore, post hoc analysis revealed no 275 
differences in the last detected follicle size prior to cover in mares receiving or not receiving 276 
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treatment. It seems, therefore, that this explanation is unsatisfactory. Studies quantifying 277 
progesterone levels following hCG administration in the mare have yielded contrasting results [39, 278 
40]. Mares treated with 1000 iu of hCG on days 3 to 5 post ovulation had enhanced day 7 to 14 279 
post oestrus progesterone concentrations [41, 42]. More recently, Köhne et al. showed that the 280 
use of 1500 iu of hCG to induce ovulation significantly increased progestin concentrations 281 
between days 5 to 15 post ovulation compared with untreated controls [39]. It is plausible that 282 
surges in progesterone levels associated with gonadotrophic preparations may bring similar 283 
benefits in horses to those seen in cattle [15, 16] although this remains speculative at this point. A 284 
further mechanism worthy of consideration is the finding of increased ovarian vascular perfusion 285 
and luteal blood flow in GnRH or hCG treated mares when compared to saline treated controls 286 
[40].  Improved ovarian blood flow may result in a higher quality corpus luteum better able to 287 
support the developing vesicle.  288 
 289 
Contradictory results have previously been found when ascertaining the relationship between 290 
uterine cysts and EPL. A study from 1995 solely investigating the effects of uterine cysts on loss 291 
rates found no overall effect of cysts once mare age had been taken into account [10]. However, 292 
Miyakoshi et al. found uterine cysts greater than 10 mm in diameter to be positively associated 293 
with EPL in their multivariable analysis [2].  With mare age being accounted for but the size and 294 
number of cysts not being quantified in our current study, the presence of cystic structures was 295 
still found to increase the odds of EPL. It has been suggested that reduced uterine vascular 296 
perfusion may occur in the vicinity of cysts and impedance on embryo dynamics and implantation 297 
may result [43]. The correlation between uterine cysts and endometrial fibrosis has also been 298 
recognised [42]. Therefore, it may be that cysts are representative of underlying uterine 299 
insufficiencies rather than being directly responsible for losses. Future analyses giving 300 
consideration to the location, size and number of uterine cysts would be of benefit to allow 301 
improved management and prognostic evaluations.  302 
 303 
Whilst primary luteal insufficiency is not a well-defined cause of EPL in mares [45], experimental 304 
studies have clearly shown exogenous progesterone use in the face of an absence of luteal 305 
support to be capable of maintaining a pregnancy [46].  With a scarcity of treatment options 306 
available to clinicians in light of a pregnancy recognised of being at risk, altrenogest is often 307 
resorted to [45].  In this study we identified 128/2245 pregnancies that were treated with 308 
altrenogest starting at the first pregnancy examination. We did not include this data in the risk 309 
13 
 
factor analysis as these treatments were initiated due to signs of impeding loss such as uterine 310 
fluid accumulation, endometrial oedema, abnormal vesicle shape and a slowed heart beat [29] 311 
and as such case selection was bias. In the majority of EPL cases either progesterone inadequacy is 312 
not the cause of loss [46] or recognition of the problem is too late. A controlled study specifically 313 
attempting to accurately determine any benefits of altrenogest in these situations and or when 314 
initiated 5 days post ovulation is required but remains challenging due to the large population size 315 
that would be required.   316 
 317 
No other factor was found to have an association with EPL following multivariable analysis in the 318 
‘all pregnancies’ dataset, despite some having a significant association in the univariable analysis. 319 
The effect of foal heat breeding on EPL has been inconsistent between studies with no effect seen 320 
in a New Zealand study [19] and a significant increase in rates of loss seen when mares were bred 321 
on foal heat in two Asian studies [2, 49].   Blanchard et al. (2012) found increased odds ratios (OR) 322 
for pregnancy loss associated with the length of breeding post-partum with the OR for pregnancy 323 
loss not decreasing to 1.00 or below until day 78 post-partum. In our study, a numerically higher 324 
incidence of EPL was detected in the group of mares mated between 8 to 19 days postpartum 325 
than in any other group. However, this represented only 33/2246 pregnancies and analysis found 326 
it did not modify risk of EPL. Again these discrepancies may relate to stringent case selection and 327 
relatively few mares mated at foal heat in the current investigation. When looking at the effects of 328 
twin/triplet pregnancies on EPL, an Australian study found significantly fewer embryonic losses in 329 
mares diagnosed with a multiple pregnancy compared with a singleton pregnancy [3]. This was not 330 
repeated elsewhere [2] and a South Korean study found the reverse [49]. No association between 331 
the   incidence of EPL and vesicle number was detected in the present study. Given the rise in 332 
occurrence of multiple pregnancies seen when comparing to the previous data from 2002 (16.1% 333 
compared to 10.5%) [7], it is reassuring that no negative impacts on early pregnancy outcome 334 
were found.  335 
 336 
Pascoe et al. showed that the release of endometrial PGF2α secondary to manual twin reduction 337 
was directly related to the pressure required [17] and flunixin was found to inhibit PGF2α. This 338 
small study followed ten mares receiving no treatment with manual reduction and 40 mares which 339 
received progestagens and flunixin. A recent Kentucky study found the use of flunixin and 340 
progesterone reduce the incidence of pregnancy loss [16] but it is unclear if it was flunixin, 341 
progesterone or the combination of treatments which had this effect. Equally, as the results were 342 
14 
 
from univariable analysis the effects could have been related to differences in operators using or 343 
not using flunixin as a significant difference in incidence of EPL was found between operators. The 344 
results of the current multivariable study show flunixin to be beneficial in regards to pregnancy 345 
maintenance when used at the time of manual reduction, reducing the occurrence of EPL by a 346 
factor of 0.34. No effect of operator was elucidated. A negative association of dexamethasone on 347 
pregnancy outcome was found only in the multiple pregnancy sub population.  Dexamethasone 348 
usage has been advocated in particularly problematic mares [50]. With only 21 mares treated in 349 
this sub population, and a wide resulting 95% confidence interval (1.94, 22.1), it is likely that this 350 
effect is due to low numbers and case selection rather than being a real sequela of 351 
dexamethasone usage.  352 
 353 
Conclusion 354 
Multivariable analysis has found the mare level factors of increasing age, one previous live foal 355 
and the presence of uterine cysts to be positively associated with EPL. Evidence suggests it is 356 
oocyte deficits rather than endometrial dysfunction which are the main contributors relating mare 357 
age to EPL [20, 21, 26, 27]. Cytogenetic analysis to establish chromosomal aberrations would be 358 
beneficial to explore the pathophysiology behind oocyte-related failures. However, evidence 359 
linking uterine dysfunction to parity [34, 36] and the influence of foal number and uterine cysts 360 
seen in the present study suggest the uterus does indeed play a role in EPL. Further studies 361 
quantifying endometrial changes, for example, assessing the size and location of cysts in relation 362 
to EPL are also warranted. Therapeutically, the use of ovulatory agents were shown to result in 363 
reduced odds of EPL and flunixin given at the time of manual reduction of twin pregnancies was 364 
similarly beneficial. Despite its increasing use, intrauterine covering therapies were not found to 365 
reduce the occurrence of EPL, although it is possible their use brings other benefits such as 366 
improved conception. By taking into account the risk factors identified in this study, clinicians will 367 
be more fully equipped to make evidence-based decisions regarding therapeutic use and 368 
treatment options whilst providing stud managers with more accurate prognostic information.     369 
 370 
 371 
 372 
 373 
 374 
 375 
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Table 1. Final multivariable model of risk factors associated with early pregnancy loss (Days 15 to 395 
65) in a cohort of 1753 thoroughbred mares based in the Newmarket area of the UK over the 2013 396 
and 2014 breeding seasons (n=2245 pregnancies). Mare included as a random effect (p=0.07).  397 
Variable Level 
Odds 
ratio 
95% 
Confidence 
interval 
Wald test 
p-value 
LRT* 
p-value 
Mare age (years)  1.11 1.04, 1.18 0.001 0.001 
Number of previous live 
foals 0 Reference   0.006 
 1 3.52 1.56, 7.95 0.002  
 ≥2 2.00 0.90, 4.42 0.09  
Use of ovulatory 
induction agent# No Reference 
  
<0.001 
 
Yes 0.31 0.17, 0.55 <0.001  
Presence of uterine 
cysts No Reference   0.03 
 Yes 1.76 1.07, 2.91 0.03  
Day 15/16 vesicle size 
(mm)  0.24 0.16, 0.38 <0.001 <0.001 
*Likelihood ratio test 398 
 #3000 iu Chorulon intravenously (n=621), 2.1 mg Ovuplant® (n=1434) or 0.04 mg Receptal® (n=11) 399 
 400 
 401 
  402 
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Table 2. Final multivariable model of risk factors associated with early pregnancy loss in 344 403 
thoroughbred mares with initial multiple pregnancies (twin or triplet) based in the Newmarket 404 
area of the 405 
UK over 406 
the 2013 407 
and 2014 408 
breeding 409 
seasons. 410 
 411 
 412 
 413 
 414 
 415 
 416 
 417 
      *Likelihood ratio test  418 
      #Flunixin meglumine 50 mg/45kg IV  419 
  420 
Variable Level 
Odds 
ratio 
95% 
Confidence 
interval 
Wald 
test 
p-value 
LRT* 
p-value 
Mare age (years)  1.13 1.03, 1.25 0.009 0.009 
Use of ovulatory 
induction agent No Reference 
  
0.02 
 
Yes 0.23 0.07, 0.72 0.01  
Use of 
dexamethasone at 
cover No Reference 
  
0.006 
 
Yes 6.51 1.93, 22.0 0.003  
Use of flunixin# at 
reduction No Reference 
  
0.02 
 
Yes 0.34 0.14, 0.84 0.02  
18 
 
References 421 
[1] Rose BV, Firth M, Morris B, Roach JM, Wathes DC, Verheyen KLP, et al. Descriptive study of current 422 
therapeutic practices, clinical reproductive findings and incidence of pregnancy loss in intensively managed 423 
thoroughbred mares. Anim Reprod Sci. 2018;188:74-84. 424 
[2] Miyakoshi D, Shikichi M, Ito K, Iwata K, Okai K, Sato F, et al. Factors Influencing the Frequency of 425 
Pregnancy Loss among Thoroughbred Mares in Hidaka, Japan. Journal of Equine Veterinary Science. 426 
2012;32:552-7. 427 
[3] Nath LC, Anderson GA, McKinnon AO. Reproductive efficiency of Thoroughbred and Standardbred 428 
horses in north-east Victoria. Aust Vet J. 2010;88:169-75. 429 
[4] Campbell MLH, Sandoe P. Welfare in horse breeding. Veterinary Record. 2015;176:436-40. 430 
[5] Bosh KA, Powell D, Neibergs JS, Shelton B, Zent W. Impact of reproductive efficiency over time and mare 431 
financial value on economic returns among Thoroughbred mares in central Kentucky. Equine Vet J. 432 
2009;41:889-94. 433 
[6] Bosh KA, Powell D, Shelton B, Zent W. Reproductive performance measures among Thoroughbred 434 
mares in central Kentucky, during the 2004 mating season. Equine Vet J. 2009;41:883-8. 435 
[7] Allen WR, Brown L, Wright M, Wilsher S. Reproductive efficiency of Flatrace and National Hunt 436 
Thoroughbred mares and stallions in England. Equine Vet J. 2007;39:438-45. 437 
[8] Morris LH, Allen WR. Reproductive efficiency of intensively managed Thoroughbred mares in 438 
Newmarket. Equine Vet J. 2002;34:51-60. 439 
[9] Hanlon DW, Stevenson M, Evans MJ, Firth EC. Reproductive performance of Thoroughbred mares in the 440 
Waikato region of New Zealand: 2. Multivariable analyses and sources of variation at the mare, stallion and 441 
stud farm level. N Z Vet J. 2012;60:335-43. 442 
[10] Eilts BE, Scholl DT, Paccamonti DL, Causey R, Klimczak JC, Corley JR. Prevalence of endometrial cysts 443 
and their effect on fertility Biol Reprod Mono. 1995;1:527-32. 444 
[11] Pycock JF, Newcombe JR. Assessment of the effect of three treatments to remove intrauterine fluid on 445 
pregnancy rate in the mare. Veterinary Record. 1996;138:320-3. 446 
[12] Meyers PJ, Bowman T, Blodgett G, Conboy HS, Gimenez T, Reid MP, et al. Use of the GnRH analogue, 447 
deslorelin acetate, in a slow-release implant to accelerate ovulation in oestrous mares. Vet Rec. 448 
1997;140:249-52. 449 
[13] Pascoe RR. A possible new treatment for twin pregnancy in the mare. Equine Vet J. 1979;11:64-5. 450 
[14] Darenius K, Fredriksson G, Kindahl H. Allyl trenbolone and flunixin meglumine treatment of mares with 451 
repeated embryonic loss. Equine Vet J. 1989;21:35-9. 452 
[15] Schnobrich MR, Riddle WT, Stromberg AJ, LeBlanc MM. Factors affecting live foal rates of 453 
Thoroughbred mares that undergo manual twin elimination. Equine Vet J. 2013;45:676-80. 454 
19 
 
[16] Sheerin PC, Howard CE, LeBlanc MM, Stromberg A. Effects of operator, treatment and mare age on the 455 
live foal rate of mares after manual twin reduction. Animal Reproduction Science. 2010;121:S312-S3. 456 
[17] Pascoe DR, Pascoe RR, Hughes JP, Stabenfeldt GH, Kindahl H. Management of twin conceptuses by 457 
manual embryonic reduction: comparison of two techniques and three hormone treatments. Am J Vet Res. 458 
1987;48:1594-9. 459 
[18] Lane EA, Bijnen ML, Osborne M, More SJ, Henderson IS, Duffy P, et al. Key Factors Affecting 460 
Reproductive Success of Thoroughbred Mares and Stallions on a Commercial Stud Farm. Reprod Domest 461 
Anim. 2016;51:181-7. 462 
[19] Hanlon DW, Stevenson M, Evans MJ, Firth EC. Reproductive performance of Thoroughbred mares in 463 
the Waikato region of New Zealand: 1. Descriptive analyses. N Z Vet J. 2012;60:329-34. 464 
[20] Ball BA, Little TV, Weber JA, Woods GL. Survival of day-4 embryos from young, normal mares and aged, 465 
subfertile mares after transfer to normal recipient mares. J Reprod Fertil. 1989;85:187-94. 466 
[21] Carnevale EM, Ginther OJ. Defective oocytes as a cause of subfertility in old mares. Biology of 467 
Reproduction Monograph Series. 1995;1:209-14. 468 
[22] Sanchez JM, Franzi L, Collia F, De Diaz SL, Panal M, Dubner M. Cytogenetic study of spontaneous 469 
abortions by transabdominal villus sampling and direct analysis of villi. Prenat Diagn. 1999;19:601-3. 470 
[23] Grande M, Borrell A, Garcia-Posada R, Borobio V, Munoz M, Creus M, et al. The effect of maternal age 471 
on chromosomal anomaly rate and spectrum in recurrent miscarriage. Hum Reprod. 2012;27:3109-17. 472 
[24] Rambags BP, Krijtenburg PJ, Drie HF, Lazzari G, Galli C, Pearson PL, et al. Numerical chromosomal 473 
abnormalities in equine embryos produced in vivo and in vitro. Mol Reprod Dev. 2005;72:77-87. 474 
[25] Rose BV, Cabrera-Sharp V, Firth MJ, Barrelet FE, Bate S, Cameron IJ, et al. A method for isolating and 475 
culturing placental cells from failed early equine pregnancies. Placenta. 2016;38:107-11. 476 
[26] Rambags BP, van Boxtel DC, Tharasanit T, Lenstra JA, Colenbrander B, Stout TA. Advancing maternal 477 
age predisposes to mitochondrial damage and loss during maturation of equine oocytes in vitro. 478 
Theriogenology. 2014;81:959-65. 479 
[27] Rizzo M, Ducheyne KD, Deelen C, Beitsma M, Cristarella S, Quartuccio M, Stout TAE, de Ruijter-Villani 480 
M. Advanced mare age impairs the ability of in vitro-matured oocytes to correctly align chromosomes on 481 
the metaphase plate. Equine Vet J. 2018; epub Jul 19.  482 
[28] Ley WB, Lessard P, Bowen JM. Variability in Equine Embryonic Vesicle Diameter Detected by 483 
Ultrasonography. Journal of Equine Veterinary Science. 1988;8:72-3. 484 
[29] Ginther OJ, Bergfelt DR, Leith GS, Scraba ST. Embryonic loss in mares: Incidence and ultrasonic 485 
morphology. Theriogenology. 1985;24:73-86. 486 
[30] Morel MC, Newcombe JR, Swindlehurst JC. The effect of age on multiple ovulation rates, multiple 487 
pregnancy rates and embryonic vesicle diameter in the mare. Theriogenology. 2005;63:2482-93. 488 
[31] McDowell KJ, Sharp DC, Grubaugh W, Thatcher WW, Wilcox CJ. Restricted conceptus mobility results in 489 
failure of pregnancy maintenance in mares. Biol Reprod. 1988;39:340-8. 490 
20 
 
[32] Pascoe RR. Observations on the length and angle of declination of the vulva and its relation to fertility 491 
in the mare. J Reprod Fertil Suppl. 1979:299-305. 492 
[33] Davies Morel MC, Newcombe JR, Hinchliffe J. The relationship between consecutive pregnancies in 493 
Thoroughbred mares. Does the location of one pregnancy affect the location of the next, is this affected by 494 
mare age and foal heat to conception interval or related to pregnancy success. Theriogenology. 2009; 495 
71(7):1072-8 496 
[34] LeBlanc MM, Neuwirth L, Jones L, Cage C, Mauragis D. Differences in uterine position of reproductively 497 
normal mares and those with delayed uterine clearance detected by scintigraphy. Theriogenology. 498 
1998;50:49-54. 499 
[35] Allen WR. Proceedings of the John P. Hughes International Workshop on Equine Endometritis. Equine 500 
Vet J. 1993;25:184-93. 501 
[36] Esteller-Vico A, Liu IK, Couto S. Uterine vascular degeneration is present throughout the uterine wall of 502 
multiparous mares. Colinearity between elastosis, endometrial grade, age and parity. Theriogenology. 503 
2012;78:1078-84. 504 
[37] Woods J, Bergfelt DR, Ginther OJ. Effects of time of insemination relative to ovulation on pregnancy 505 
rate and embryonic-loss rate in mares. Equine Vet J. 1990;22:410-5. 506 
[38] Carnevale EM, Bergfelt DR, Ginther OJ. Aging effects on follicular activity and concentrations of FSH, 507 
LH, and progesterone in mares. Animal Reproduction Science. 1993;31:287-99. 508 
[39] Kohne M, Kuhl J, Ille N, Erber R, Aurich C. Treatment with human chorionic gonadotrophin before 509 
ovulation increases progestin concentration in early equine pregnancies. Anim Reprod Sci. 2014;149:187-510 
93. 511 
[40] Brito LF, Baldrighi JM, Wolf CA, Ginther OJ. Effect of GnRH and hCG on progesterone concentration and 512 
ovarian and luteal blood flow in diestrous mares. Anim Reprod Sci. 2017;176:64-9. 513 
[41] Kelly CM, Hoyer PB, Wise ME. In-vitro and in-vivo responsiveness of the corpus luteum of the mare to 514 
gonadotrophin stimulation. J Reprod Fertil. 1988;84:593-600. 515 
[42] Michel TH, Rossdale PD, Cash RS. Efficacy of human chorionic gonadotrophin and gonadotrophin 516 
releasing hormone for hastening ovulation in thoroughbred mares. Equine Vet J. 1986;18:438-42. 517 
[43] Ferreira JC, Gastal EL, Ginther OJ. Uterine blood flow and perfusion in mares with uterine cysts: effect 518 
of the size of the cystic area and age. Reproduction. 2008;135:541-50. 519 
[44] Kenney RM. Cyclic and pathologic changes of the mare endometrium as detected by biopsy, with a 520 
note on early embryonic death. J Am Vet Med Assoc. 1978;172:241-62. 521 
[45] Allen WR. Luteal deficiency and embryo mortality in the mare. Reprod Domest Anim. 2001;36:121-31. 522 
[46] Hinrichs K, Sertich PL, Palmer E, Kenney RM. Establishment and maintenance of pregnancy after 523 
embryo transfer in ovariectomized mares treated with progesterone. J Reprod Fertil. 1987;80:395-401. 524 
[47] Vanderwall DK. Early Embryonic Loss in the Mare. Journal of Equine Veterinary Science. 2008;28:691-525 
702. 526 
21 
 
[48] Irvine CH, Sutton P, Turner JE, Mennick PE. Changes in plasma progesterone concentrations from days 527 
17 to 42 of gestation in mares maintaining or losing pregnancy. Equine Vet J. 1990;22:104-6. 528 
[49] Yang YJ, Cho GJ. Factors concerning early embryonic death in thoroughbred mares in South Korea. J 529 
Vet Med Sci. 2007;69:787-92. 530 
[50] Bucca S, Carli A, Buckley T, Dolci G, Fogarty U. The use of dexamethasone administered to mares at 531 
breeding time in the modulation of persistent mating induced endometritis. Theriogenology. 2008;70:1093-532 
100. 533 
 534 
 Supplementary Table 1. Descriptive and univariable analysis results of potential A. mare B. 
stallion C. therapeutic and D. pregnancy risk factors for early pregnancy loss (EPL) in a 
cohort of 1753 thoroughbred mares (2245 pregnancies) in the Newmarket region of the UK 
in the 2013 and 2014 breeding seasons. ‘Mare’ was included in the models as a random 
effect to account for repeat pregnancies in the same mare.  
 
Supplementary Table 1A. 
 Variable  Level n 
EPL                
n 
% EPL 
95% confidence 
interval  
(EPL incidence) 
OR 
95% 
confidence 
interval 
(OR) 
Likelihood 
ratio test  
p-value 
Mare age 
(n=2239)  2 1 0 0.0 0.0, 95.0 1.14* 1.09, 1.18 <0.001 
 
3 38 0 0.0 0.0, 7.6 
   
 
4 269 7 2.6 1.1, 5.3 
   
 
5 266 16 6.0 3.5, 9.6 
   
 
6 261 12 4.6 2.4, 7.9 
   
 
7 218 10 4.6 2.2, 8.3 
   
 
8 184 15 8.2 4.6, 13.1 
   
 
9 165 10 6.1 2.9, 10.9 
   
 
10 148 10 6.8 3.3, 12.1 
   
 
11 133 17 12.8 7.6, 19.7 
   
 
12 111 16 14.4 8.5, 22.4 
   
 
13 97 16 16.5 9.7, 25.4 
   
 
14 88 12 13.6 7.2, 22.6 
   
 
15 68 10 14.7 7.3, 25.4 
   
 
16 59 6 10.2 3.8, 20.8 
   
 
17 51 6 11.8 4.4, 23.9 
   
 
18 34 5 14.7 5.0, 31.1 
   
 
19 21 3 14.3 3.0, 36.3 
   
 
20 17 5 29.4 10.3, 56.0 
   
 
21 6 0 0.0 0.0, 39.3 
   
 
22 3 1 33.3 0.8, 90.6 
   
 
24 1 0 0.0 0.0, 95.0 
   Mare 
status 
(n=2245)  maiden 416 13 3.1 1.7, 5.3 Reference 
 
<0.001 
 
barren 308 34 11.0 7.8, 15.1 3.70 1.86, 7.38 
 
 
foaled 1407 122 8.7 7.3, 10.3 3.06 1.67, 5.61 
 
 
rested 114 9 7.9 3.7, 14.5 2.73 1.08, 6.88 
 EPL 
previous 
season 
(n=1542) no 1423 91 6.4 5.2, 7.8 Reference 
 
0.05 
 
yes 119 15 12.6 7.2, 19.9 2.01 1.07, 3.77 
 Previous 
live foals 0 469 14 3.0 1.6, 5.0 Reference 
 
<0.001 
Supplementary Table 1
(n=2206  
 
1 347 30 8.6 5.9, 12.1 3.20 1.61, 6.33 
  2-5 840 63 7.5 5.8, 9.5 2.69 1.45, 5.00  
 
6+ 550 69 12.5 9.9, 15.6 4.98 2.67, 9.30 
 Number 
of cycles 
covered 
(n=2234)  1 1655 125 7.6 6.3, 8.9 Reference 
 
0.48 
 
2 455 42 9.2 6.7, 12.3 1.28 0.86, 1.92 
 
 
≥3 124 10 8.1 3.9, 14.3 1.04 0.50, 2.17 
 Uterine 
cysts  
(n=2245) no 1844 122 6.6 5.5, 7.8 Reference 
 
<0.001 
 
yes 401 56 14.0 10.7, 17.7 2.40 1.64, 3.50 
 Days 
from 
foaling to 
cover 
(n=1346) 8-19 33 4 12.1 3.4, 28.2 Reference 
 
0.80 
 
20-89 1284 110 8.6 7.1, 10.2 0.67 0.20, 2.22 
 
 
90+ 29 3 10.3 2.2, 27.4 0.57 0.09, 3.58 
 Month of 
cover 
(n=2243) Feb 304 17 5.6 3.3, 8.8 Reference  0.43 
 March 677 48 7.1 5.3, 9.3 1.32 0.72, 2.43  
 April 673 58 8.6 6.6, 11.0 1.64 0.90, 2.98  
 May 514 47 9.1 6.8, 12.0 1.67 0.91, 3.10  
 June/July 75 7 9.3 3.8, 18.3 1.51 0.55, 4.15  
Uterine 
fluid (cm) 
(n=2201) 0 1449 116 8.0 6.7, 9.5 Reference  0.37 
 1 525 37 7.0 5.0, 9.6 0.84 0.55, 1.29  
 2 147 13 8.8 4.8, 14.6 1.10 0.56, 2.16  
 ≥3 80 3 3.8 0.8, 10.6 0.41 0.12, 1.42  
*Mare age modelled as a continuous variable 
 
Supplementary Table 1B 
Variable  Level n 
EPL  
n 
% EPL 
95% 
confidence 
interval (EPL 
incidence) 
OR 
95% 
confidence 
interval 
(OR) 
Likelihood 
ratio test        
p-value 
Stallion age 
(n=2165) 3-5 310 26 8.4 5.6, 12.0 Reference 
 
0.40 
 
6-9 748 54 7.2 5.5, 9.3 0.83 0.49, 1.41 
 
 
10-13 518 51 9.8 7.4, 12.7 1.19 0.69, 2.07 
 
 
14-18 294 19 6.5 3.9, 9.9 0.74 0.38, 1.45 
 
 
19+ 295 21 7.1 4.5, 10.7 0.80 0.42, 1.55 
  
  
 
 
Supplementary Table 1C 
Variable  Level n 
EPL                
n 
% EPL 
95% 
confidence 
interval  
(EPL incidence) 
OR 
95% 
confidence 
interval 
(OR) 
Likelihood 
ratio test 
p-value 
Pre-oestrus PG 
(n=2245) no 1584 120 7.6 6.3, 9.0 Reference 
 
0.56 
 
yes 661 58 8.8 6.7, 11.2 1.11 0.78, 1.59 
 
         Pre-oestrus 
altrenogest 
(n=2245) no 2106 167 7.9 6.8, 9.2 Reference 
 
0.98 
 
yes 139 11 7.9 4.0, 13.7 1.01 0.50, 2.01 
          Pre-oestrus 
domperidone 
(n=2245) no 2195 175 8.0 6.9, 9.2 Reference 
 
0.59 
 
yes 50 3 6.0 1.3, 16.5 0.72 0.20, 2.54 
 
         Pre-oestrus 
sulpiride 
(n=2245) no 2187 172 7.9 6.8, 9.1 Reference 
 
0.45 
 
yes 58 6 10.3 3.9, 21.2 1.46 0.56, 3.76 
 
         Pre-oestrus P 
and E (n=2245) no 2195 172 7.8 6.7, 9.0 Reference 
 
0.40 
 
yes 50 6 12.0 4.5, 24.3 1.54 0.58, 4.09 
 
         Ovulatory 
induction agent 
(n=2245) no 183 36 19.7 14.2, 26.2 Reference 
 
<0.001 
 
yes 2062 142 6.9 5.8, 8.1 0.26 0.16, 0.42 
 
         Intrauterine 
antibiotics at 
cover (n=2245) no 1132 86 7.6 6.1, 9.3 Reference 
 
0.78 
 
yes 1113 92 8.3 6.7, 10.0 1.05 0.75, 1.47 
 
         Dexamethasone 
at cover 
(n=2245) no 2081 163 7.8 6.7, 9.1 Reference 
 
0.63 
 
yes 164 15 9.1 5.2, 14.6 1.16 0.63, 2.14 
 
         
Oxytocin at 
cover (n-2245) no 1090 95 8.7 7.1, 10.5 Reference 
 
0.15 
 
yes 1155 83 7.2 5.8, 8.8 0.78 0.55, 1.10 
 
         Intrauterine 
lavage at cover 
(n=2245) no 1718 135 7.9 6.6, 9.2 Reference 
 
0.92 
 
yes 527 43 8.2 6.0, 10.8 0.98 0.66, 1.46 
  
 
 
Supplementary Table 1D 
Variable  Level n 
EPL                
n 
% EPL 
95% confidence 
interval  
(EPL incidence) 
OR 
95% 
confidence 
interval 
(OR) 
Likelihood 
ratio test         
p-value 
Number of 
vesicles 
(n=2241) 1 1881 148 7.9 6.7, 9.2 Reference 
 
0.93 
 
2 344 27 7.8 5.2, 11.2 0.98 0.61, 1.56 
 
 
3 16 1 6.3 0.2, 30.2 0.66 0.07, 5.96 
 
         Size of vesicle 
at day 15/16 
(mm) 
(n=1881) 0-10 90 21 23.3 15.1, 33.4 0.26* 0.17, 0.39 <0.001 
 
11-20 1111 98 8.8 7.2, 10.6 
   
 
21-30 658 25 3.8 2.5, 5.6 
   
 
31-40 22 0 0.0 0.0, 12.7 
   *Vesicle size modelled as a continuous variable; size grouped into 10mm intervals to illustrate EPL incidence in 
each category 
 
Supplementary Table 2. Descriptive and univariable analysis results of potential A. mare B. 
stallion C. therapeutic D. pregnancy risk factors for early pregnancy loss in a cohort of 344 
thoroughbred mares with multiple (twin/triplet) pregnancies in the Newmarket region of 
the UK in the 2013 and 2014 breeding seasons.  
 
Supplementary Table 2A 
Variable  Level n 
EPL                
n 
% EPL 
95% confidence 
interval  
(EPL incidence) 
OR 
95% 
confidence 
interval 
(OR) 
Likelihood 
ratio test  
p-value 
Mare age 
(n=341) 3 9 0 0.0 0.0, 28.3 1.13* 1.04, 1.23 0.006 
 
4 54 1 1.9 0.0, 9.9 
   
 
5 39 3 7.7 1.6, 20.9 
   
 
6 27 2 7.4 0.9, 24.3 
   
 
7 28 2 7.1 0.9, 23.5 
   
 
8 20 0 0.0 0.0, 13.9 
   
 
9 26 0 0.0 0.0, 10.9 
   
 
10 25 0 0.0 0.0, 11.3 
   
 
11 22 2 9.1 1.1, 29.2 
   
 
12 15 2 13.3 1.7, 40.5 
   
 
13 16 2 12.5 1.6, 38.3 
   
 
14 9 4 44.4 13.7, 78.8 
   
 
15 11 2 18.2 2.3, 51.8 
   
 
16 12 3 25.0 5.5, 57.2 
   
 
17 15 2 13.3 1.7, 40.5 
   
 
18 5 0 0.0 0.0, 45.1 
   
 
19 2 0 0.0 0.0, 77.6 
   
 
20 5 0 0.0 0.0, 45.1 
   
 
21 1 0 0.0 0.0, 95.0 
   
         Mare 
status 
(n=344) maiden 89 4 4.5 1.2, 11.1 Reference 
 
0.13 
 
barren 67 9 13.4 6.3, 24.0 3.30 0.97, 11.22 
 
 
foaled 166 13 7.8 4.2, 13.0 1.81 0.57, 5.71 
 
 
rested 22 0 0.0 0.0, 12.7 0  - 
 
         EPL 
previous 
season 
(n=240) no 213 10 4.7 2.3, 8.5 Reference 
 
0.004 
 
yes 27 6 22.2 8.6, 42.3 5.80 1.92, 17.55 
 
         Live foals 
(n=337) 0 98 4 4.1 1.1, 10.1 Reference 
 
0.09 
 
1-5 142 10 7.0 3.4, 12.6 1.78 0.54, 5.85 
 
 
6+ 97 12 12.4 6.6, 20.6 3.32 1.03, 10.68 
 
         
Supplementary Table 2
 Variable  Level n 
EPL                
n 
% EPL 
95% confidence 
interval  
(EPL incidence) 
OR 
95% 
confidence 
interval 
(OR) 
Likelihood 
ratio test  
p-value 
Number of 
cycles 
covered 
(n=344)  1 275 20 7.3 4.5, 11.0 Reference 
 
0.92 
 
2 56 5 8.9 3.0, 19.6 1.25 0.45, 3.48 
 
 
≥3 13 1 7.7 0.0, 36.0 1.06 0.13, 8.59 
 
         Uterine 
cysts 
(n=343) no 287 17 5.9 3.5, 9.3 Reference 
  
 
yes 56 9 16.1 7.6, 28.3 3.04 1.28, 7.23 0.02 
         Days from 
foaling to 
cover 
(n=153) 10-19 5 1 20.0 0.5, 71.6 Reference 
 
0.38 
 
20+ 148 11 7.4 3.8, 12.9 0.32 0.03, 3.13 
   
        Month of 
cover 
(n=344) 
Feb 62 4 6.5 1.8, 15.7 Reference  0.73 
 
March 111 9 8.1 3.8, 14.8 1.28 0.38, 4.34  
 
April 95 5 5.3 1.7, 11.9 0.81 0.21, 3.12  
 
May 70 7 10.0 4.1, 19.5 1.61 0.45, 5.79  
 
June 6 1 16.7 0.4, 64.1 2.90 0.27, 31.15  
Uterine 
fluid (cm) 
(n=343) 0 222 17 7.7 4.5, 12.0 Reference 
 
0.81 
 
1-2 107 9 8.4 3.9, 15.4 1.11 0.48, 2.57 
    ≥3 14 0 0.0 0.0, 19.3 0 - 
 *Mare age modelled as a continuous variable 
 
 
 
 
 
 
 
Supplementary Table 2B 
Variable  Level n 
EPL                
n 
% EPL 
95% 
confidence 
interval  
(EPL incidence) 
OR 
95% 
confidence 
interval  
(OR) 
Likelihood  
ratio test  
p-value 
Stallion age 
(n=339) 3-5 76 6 7.9 3.0, 16.4 Reference 
 
0.86 
 
6-9 103 6 5.8 2.2, 12.2 0.72 0.22, 2.33 
 
 
10-13 85 8 9.4 4.2, 17.7 1.21 0.40, 3.67 
 
 
14-18 35 3 8.6 1.8, 23.1 1.09 0.26, 4.65 
 
 
19+ 40 2 5.0 0.6, 16.9 0.61 0.12, 3.19 
  
 
 
Supplementary Table 2C 
Variable  Level n 
EPL                
n 
% EPL 
95% 
confidence 
interval  
(EPL incidence) 
OR 
95% 
confidence 
interval  
(OR) 
Likelihood 
ratio test  
p-value 
Pre-oestrus PG 
(n=344) no 219 18 8.2 4.9, 12.7 Reference 
 
0.53 
 
yes 125 8 6.4 2.8, 12.2 0.76 0.32, 1.81 
 
         Pre-oestrus 
altrenogest (n=344) no 322 24 7.5 4.8, 10.9 Reference 
 
0.78 
 
yes 22 2 9.1    1.1, 29.2 1.24 0.27, 5.63 
 
         Pre-oestrus 
domperidone 
(n=344) no 336 25 7.4 5.1, 10.8 Reference 
 
0.62 
 
yes 8 1 12.5 0.1, 49.2 1.78 0.21, 15.02 
 
         Pre-oestrus sulpiride 
(n=344) no 337 25 7.4 4.9, 10.8 Reference 0.54 
 
yes 7 1 14.3 0.4, 57.9 2.08 0.24, 17.96 
 
         Pre-oestrus P and E 
(n=344) no 334 25 7.5 4.9, 10.9 Reference 0.78 
 
yes 10 1 10.0 0.3, 44.5 1.37 0.17, 11.28 
 
         Ovulatory induction 
agent (n=344) no 23 5 21.7 7.5, 43.7 Reference 
 
0.02 
 
yes 321 21 6.5 4.1, 9.8 0.25 0.09, 0.75 
 
         Intrauterine 
antibiotics at cover no 170 11 6.5 3.3, 11.3 Reference 0.45 
(n=344) 
 
yes 174 15 8.6 4.9, 13.8 1.36 0.61, 3.06 
 
         Dexamethasone at 
cover (n=334) no 323 21 6.5 4.1, 9.8 Reference 0.02 
 
yes 21 5 23.8 8.2, 47.2 4.49 1.50, 13.46 
 
         Oxytocin at cover 
(n=344) no 174 13 7.5 4.0, 12.4 Reference 0.95 
 
yes 170 13 7.6 4.1, 12.7 1.03 0.46, 2.28 
 
         Intrauterine lavage at 
cover (n=344) no 259 17 6.6 3.9, 10.3 Reference 0.24 
 
yes 85 9 10.6 5.0, 19.2 1.69 0.72, 3.94 
  
 
 
 
Supplementary Table 2D 
Variable Level n 
EPL 
n 
% EPL 
95% 
confidence 
interval  
(EPL incidence) 
OR 
95% 
confidence 
interval  
(OR) 
Likelihood  
ratio test  
p-value 
Number of vesicles 2 327 25 7.6 5.0, 11.1 Reference 0.78 
 3 17 1 5.9 0.1, 28.7 0.76 0.10, 5.93 
 Ovulation (n=240) multiple 
same ovary 141 7 5.0 2.0, 10.0 Reference 0.21 
 bilateral 99 9 9.1 4.2, 16.6 1.91 0.69, 5.33 
 Size of vesicle at day 
15/16 (mm) (n=262) 0-10 16 0 0 0.0, 17.1 0.0 - 0.48 
 
11-20 173 14 8.1 4.5, 13.2 
 
 
Reference 
  21-30 72 4 5.6 1.5, 13.6 0.67 0.21, 2.10 
 31-40 1 0 0.0 0.0, 95.0 0.0 -  
Flunixin (n=344) no 136 15 11.0 6.3, 17.5 Reference 
 
0.05 
 yes 208 11 5.3 2.7, 9.3 0.45 0.20, 1.01 
 Buscopan (n=344) no 336 26 7.7 5.1, 11.1 Reference 
   yes 8 0 0.0 0.0, 31.2 0.00 - 
 Sedation (n=344) no 262 23 8.8 5.6, 12.9 Reference 
 
0.10 
 yes 82 3 3.7 0.8, 10.3 0.39 0.12, 1.35 
 Same location at 
reduction (n=249) no 157 8 5.1 2.2, 9.8 Reference 
 
0.10 
 yes 92 10 10.9 5.3, 19.1 2.27 0.86, 5.98 
 Vet (n-344) V01 16 0 0.0 0.0, 17.1 0.00 - 0.27 
 V02 50 4 8.0 2.2, 19.2 0.62 0.18, 2.19  
 V03 5 0 0.0 0.0, 45.1 0.00 -  
 V04 89 4 4.5 1.2, 11.1 0.34 0.10, 1.17  
 V05 65 8 12.3 5.5, 22.8 Reference 
 
 
 V06 2 1 50.0 12.6, 98.7 7.13 0.40, 125.52  
 V07 34 2 5.9 0.7, 19.7 0.45 0.09, 2.23  
 V10 2 0 0.0 0.0, 77.6 0.00 -  
 V11 54 3 5.6 1.2, 15.4 0.42 0.11, 1.67  
 V12 14 3 21.4 4.7, 50.8 1.94 0.44, 8.50  
 V13 13 1 7.7 0.2, 36.0 0.59 0.07, 5.20  
 
